July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-...
According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent re...
At the 96th Congress of the International Association for Dental Research (IADR), Benjamin Chaffee of the University of California, San Francisco published a report on nicotine and carcinogens in toba...
Even with surgery, radiotherapy, chemotherapy, and/or gene-targeted therapy (such as cetuximab), the five-year survival rate for locally advanced head and neck cancer is only 46%. Usually, the treat...
According to a new study by Stanford University School of Medicine, a compound found in citrus oil may help relieve dry mouth symptoms caused by radiation therapy in head and neck cancer patients. Th...
In patients with metastatic malignant melanoma, the combination of ipilimumab ( CTLA4 antibody) and programmed death (PD)-1 inhibitor nivolumab can significantly improve the prognosis compared with ...
Compared with other malignant tumors such as non-small cell lung cancer (NSCLC) and breast cancer, head and neck squamous cell carcinoma (HNSCC) is relatively rare in the United States. There are abo...
Mr. Xu is a typical Chongqing native. He is naturally spicy and unhappy. Among all the spicy foods, Chongqing spicy hot pot is his favorite. However, unfortunately, a malignant tumor with a parotid ...
The University of Athens Strati A et al. reported that whether PD-L1 is overexpressed in circulating tumor cells (CTC) can provide more feasible and important prognostic information for patients wit...
The report by Kershena Liao of Baylor College of Medicine in the United States and more fully understand the process of head and neck oncologists considering switching to palliative care, which can ...